NCI-MATCH/EAY131 TRIAL UPDATE

A series of changes were recently incorporated in NCI-MATCH/EAY131 addendum #24. First, two new correlative proposals, CS-MATCH-0014ctR and CS-MATCH-0015ctR, were adapted into appendices for the master protocol. Revisions were implemented for multiple pre-existing sub-protocols (approximately 17 arms), including the following: modifications to improve slow accruing arms — aMOI additions; expansion of arms EAY131-C1 (15), H (50), M (14), and Z1C (14) with justification; modifications to affected sub-protocols to account for the copy number amplification threshold; adaptation of new correlative proposal CS-MATCH-0012 into appendices for sub-protocol EAY131-Q; revisions to the IHC enrollment process, affecting sub-protocols EAY131-Z1G and Z1H; and RRAs for trametinib, dabrafenib, and palbociclib affecting arms EAY131-H, R, S1, S2, Z1C.

Additionally, both orthogonal assay language and nucleic acid language were added to the master screening document, as well as revised novel inclusionary and exclusionary aMOI language. Finally, minor administrative edits were made throughout the master and screening consent documents. For questions or more information, email eamatchpm@ecog-acrin.org.

The Journal of Clinical Oncology reports results for Arm Z1D of NCI-MATCH, investigating the activity of nivolumab in 18 different cancer types, mostly rare and none colorectal, with DNA repair defects. The 36% response rate across a range of cancers compares well with a previous 31% response in colon cancer. Read more.